Ferring’s Fecal Transplant Gets Through AdComm, Aided By Preference For Standardized Product

US FDA's Vaccines and Related Biological Products Advisory Committee endorses Rebyota for recurrent C. difficile infection; most panelists prefer a product whose manufacturing will be regulated, even one with lingering concerns about efficacy or safety, over the current landscape.

How Rebyota might change the regulatory landscape for unapproved fecal transplants was among the advisory committee's considerations. • Source: Shutterstock

Ferring Pharmaceuticals’s fecal microbiota transplant for recurrent Clostridioides difficile infection received a favorable US Food and Drug Administration advisory committee review on 22 September thanks in large part to agency advisers’ preference for more quality control and standardization in a space that has been dominated by unapproved products due to FDA enforcement discretion.

The desire for a regulated product trumped acknowledged gaps in the data package submitted for approval for most Vaccine and...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers